Results 131 to 140 of about 59,209 (259)
Alimentary Pharmacology &Therapeutics, Volume 62, Issue 5, Page 483-492, September 2025.Disease clearance was achievable with ustekinumab intravenous induction and subcutaneous maintenance treatment in patients with moderately to severely active ulcerative colitis. Early disease clearance was associated with favourable long‐term outcomes, including symptomatic remission, improved HRQoL and longer time‐to‐treatment failure.
Silvio Danese +5 more
wiley +1 more source
Cancer Medicine, Volume 14, Issue 15, August 2025.ABSTRACT Introduction Soft tissue sarcomas are a diverse group of rare cancers, with approximately 15%–20% found in the retroperitoneum. Liposarcomas (LPS) make up approximately half of all retroperitoneal (RP) sarcomas, with most cases classified as either well‐differentiated (WD) or dedifferentiated (DD).
Steven Sun +2 more
wiley +1 more source
Current and Emerging Autoantibodies in Ulcerative Colitis
European Journal of Immunology, Volume 55, Issue 8, August 2025.Autoantibodies in ulcerative colitis target neutrophil and mucosal components, including NETs, goblet cells, and integrins‐offering insight into disease pathophysiology. Understanding these interactions may support biomarker development, enable earlier diagnosis, aid patient stratification, and drive future therapeutic innovation.
Erick A. Mendieta‐Escalante +2 more
wiley +1 more source
Health Science Reports, Volume 8, Issue 8, August 2025.ABSTRACT Background and Aims The incidence of inflammatory bowel disease (IBD), characterized by chronic gastrointestinal inflammation, has significantly increased over the last two decades. Concurrently, advancements in treatment strategies have accelerated, aiming not only to induce but also to maintain remission.
Mayank Jha +9 more
wiley +1 more source
Intestinal Obstruction Following Total Colectomy for Ulcerative Colitis*
, 1961 G. E. Tolstedt, Jonathan Bell
openalex +2 more sources
JPGN Reports, Volume 6, Issue 3, Page 305-308, August 2025.Abstract The treatment options available for pediatric ulcerative colitis (UC) are challenging due to few with Federal Drug Administration approval. Newer medications approved for adults include additional biologics with differing mechanisms of action and small molecule drugs, such as Janus kinase (JAK) inhibitors.
Jessica A. Black, Brad Pasternak
wiley +1 more source
Diffuse ischemic colitis associated with systemic lupus erythematosus-response to subtotal colectomy
, 1978 Martin Kistin +2 more
openalex +1 more source